Ceva launches new congestive heart failure therapy for dogs

Animal Health Supplier News

Ceva Animal Health has announced the launch of a new and improved spironolactone therapy for congestive heart failure caused by degenerative mitral valve disease in dogs.

Prilactone Next has been designed as a popular spironolactone products Priclactone and Tempora, which are set to be discontinued following the launch of the newer medicine.

“Ceva Animal Health is launching Prilactone Next, a new treatment for congestive heart failure caused by degenerative mitral valve disease in dogs.“

It is available in three presentations of 10mg, 50mg and 100mg, and comes in chewable tablets that can be easily split to achieve the required dose, depending on the size and weight of the dog.

The packaging contains three blisters of ten tablets for the 10mg and 50mg presentations and three blisters of eight tablets for the 100mg presentation, for easy dispensing and storage in practice.

Nicola Barclay, product manager at Ceva Animal Health, said: "Prilactone Next is an improved, easy-to-administer spironolactone that enables owners to accurately treat their pets and will further enhance our existing cardiology range."

Other brands in the Ceva cardiology range include Cardalis, Libeo and Nelio.

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Animal Health
Return to news